Overview & Definition
Thalassemia is an inherited genetic blood disorder characterized by reduced or absent production of globin chains required to form hemoglobin, leading to severe chronic anemia and bone marrow expansion.
Types & Classification
- Beta Thalassemia Major (Cooley’s Anemia)
- Beta Thalassemia Intermedia
- Beta Thalassemia Minor (Trait)
- Alpha Thalassemia Major (Hb H Disease)
- Alpha Thalassemia Trait
Underlying Causes & Risk Factors
- Inherited genetic mutations in HBB or HBA genes
- Autosomal recessive inheritance from carrier parents
Common Symptoms & Warning Signs
Diagnostic Evaluation
Accurate diagnosis requires comprehensive laboratory investigation under expert hematological supervision:
- 🔍 Hemoglobin Electrophoresis & HPLC Analysis
- 🔍 Complete Blood Count (RBC Indices: low MCV, low MCH)
- 🔍 DNA Mutation Analysis & Genetic Counseling
- 🔍 Serum Ferritin & Cardiac/Liver MRI (T2*) Iron Assessment
Treatment Options & Clinical Management
- 💊 Lifelong Hypertransfusion Therapy – regular 2–4 weekly leukoreduced packed RBC transfusions to maintain baseline Hemoglobin >9.5–10 g/dL and suppress ineffective erythropoiesis.
- 💊 Iron Chelation Therapy – daily oral iron chelators (Deferasirox or Deferiprone) or SC Deferoxamine to remove excess iron and prevent cardiac/hepatic siderosis.
- 💊 Erythroid Maturation Agent (Luspatercept) – reduces transfusion burden in adult patients with transfusion-dependent beta thalassemia.
- 💊 Allogeneic Hematopoietic Stem Cell Transplant – established curative treatment option for young patients with a matched sibling donor.
- 💊 Autologous CRISPR Gene Editing Therapy (Exagamglogene autotemcel) – FDA-approved gene editing therapy for eligible patients with transfusion-dependent beta thalassemia.
Frequently Asked Questions
Early symptoms appear in early infancy (6–24 months) and include severe paleness, poor feeding, failure to thrive, abdominal swelling due to hepatosplenomegaly, jaundice, and facial bone changes (frontal bossing) if transfusion is delayed.
Diagnosis requires a Complete Blood Count showing severe microcytic hypochromic anemia (low MCV, low MCH), High-Performance Liquid Chromatography (HPLC) or Hemoglobin Electrophoresis (quantifying HbF and HbA2), serum Ferritin, T2* MRI for cardiac/hepatic iron assessment, and molecular DNA mutation testing.